Takeda shares positive Phase IIIb data; NIA grant for Phase II study on new oral Alzheimer's treatment
→ Takeda says its VARSITY, Phase IIIb study “demonstrated that the gut-selective biologic vedolizumab (Entyvio) was superior to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
